Idebenon (2, reassessment) (Raxone®) – Leber's hereditary optic neuropathy (LHOP)

Characteristics

Start date 01.04.2022
Resolution 15.09.2022
INN Idebenon
Brand name Raxone®
Pharm. company Chiesi GmbH
G-BA procedure ID 2022-04-01-D-807
Therapeutic area Eye diseases ORPHAN
Reason for procedure Reassessment: G-BA limitation
Original resolution: Idebenon (17.03.2016)
Regulatory status Exceptional Circumstances

G-BA resolution "Anwendungsgebiet des Beschlusses" (German)

Adolescents and adults with visual disturbances due to Leberhereditary Optic Neuropathy (LHON)

Subpopulation Indication Comparator
Adolescents and adults with visual disturbances due to Leberhereditary Optic Neuropathy (LHON) Not applicable

9. Associated procedures



<< List of all resolutions